Abstract
A monthly injectable contraceptive combining estradiol cypionate and medroxyprogesterone acetate was found to be well tolerated and effective in a phase III prospective, multicenter trial conducted in the United States. In this open-label comparison with an oral contraceptive, there were no pregnancies in the group receiving the monthly combination injectable contraceptive versus one pregnancy in those receiving the oral contraceptive. The rates of discontinuation for adverse events in the two treatment groups over the 60-week trial did not differ significantly. The majority of patients in both groups reported satisfaction with the method of contraception which they were receiving.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 15-18 |
| Number of pages | 4 |
| Journal | Gynecological Endocrinology |
| Volume | 15 |
| Issue number | SUPPL. 3 |
| State | Published - Sep 22 2001 |
Keywords
- EC/MPA
- Estradiol cypionate
- Hormonal contraception
- Medroxyprogesterone acetate
- Monthly injectable contraception
- Oral contraception
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology
- Obstetrics and Gynecology
